As Central Florida’s population grows, the need for a high-quality, well-trained health care workforce grows alongside it.
To ensure the region’s future health care needs are met, AdventHealth is working with community partners to educate and train student nurses in a real-world setting.
Across Central Florida, AdventHealth has been establishing dedicated education units, or DEUs, where students work intensively with nurse leaders known as preceptors. At AdventHealth East Orlando, students from the University of Central Florida’s College of Nursing began working this fall on a DEU alongside AdventHealth nurses.
“Working with our great team members, and treating real-life patients, offers invaluable experience to student nurses,” said Lydia Hendrix, chief nursing officer at AdventHealth East Orlando. “We appreciate our partnership with UCF and look forward to collaborating for years to come as we address our workforce challenges.”
Read more about the DEU, and the collaborative work being done by AdventHealth, Orlando Health and the University of Central Florida to train the nursing workforce of the future, here.
12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
AdventHealth Celebration Team Performs First-in-World Procedure Targeting Kidney Tumor with Sound Beams
Kidney-tumor patients have an innovative new treatment option, first performed recently by a surgical team at AdventHealth Celebration.
Podcast
Test Apple Podcast - All Episodes
Test Apple Podcast
Social Media Post
AdventHealthMD Social Media Post Test - Consumer Title
As the Official Healthcare Provider of the 2024 NASCAR Chicago Street Race, we’re thrilled to support such a memorable experience with this amazing community.
News
Clone of AdventHealth Celebration Team Performs First-in-world Procedure Targeting Kidney Tumor with Sound Beams
The innovative new treatment targets and destroys tumors using sound beams, noninvasively and without the need for needles and incisions.
Media Coverage
Consumer Title - AdventHealthMD Media Coverage Test
A summary of the article goes here. A summary of the article goes here. A summary of the article goes here. A summary of the article goes here.
News
AdventHealth Celebration Team Performs First-in-world Procedure Targeting Kidney Tumor with Sound Beams
The innovative new treatment targets and destroys tumors using sound beams, noninvasively and without the need for needles and incisions.
Video
Dr. Corbin on the gut microbiome research study
Dr. Corbin on the gut microbiome research study
News
Genetic Testing at AdventHealth Alerts Woman, Doctors to Aggressive Cancer Before it Develops
A genetic test, originally conducted to help better understand her daughter's diagnosis, revealed Samantha Arceneaux carries a genetic variant that virtually guarantees she will develop an aggressive...
News
AdventHealth Clinical Research Unit Recruiting Patients with Solid Tumors Harboring MTAP Deletion for Phase I Clinical Trial
Under the leadership of investigator Guru Sonpavde, MD, AdventHealth’s Clinical Research Unit (CRU), a collaborative between the AdventHealth Cancer Institute and AdventHealth Research Institute, is...
News
AdventHealth Research Institute conducting two studies on the impact of shift work on healthcare workers’ health
The AdventHealth Research Institute recently launched two new clinical studies to better understand and address the needs of healthcare employees who work night shifts.
News
AdventHealth Celebration Successfully Performs First Robotics-assisted Cochlear Implant Procedure in Florida with the iotaSOFT® Insertion System.
In January 2024, AdventHealth Celebration neurotologist Michael Seidman, MD, FACS, became the first in Florida and the Southeast to complete a robotics-assisted cochlear implant procedure using the...
News
New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma
The CheckMate 901 Phase III clinical trial results, recently published in the New England Journal of Medicine, found that combining the programmed death 1 (PD1) inhibitor immunotherapy nivolumab with...